• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

AAOpt 2022: ODs are seeing new and exciting updates in the ophthalmic therapeutic space


Jessica Steen, OD, FAAO, gave an ophthalmic therapeutic update during the 2022 American Academy of Optometry Meeting.

Jessica Steen, OD, FAAO, assistant professor at Nova Southeastern University College of Optometry, shares key takeaways from her 2022 AAOpt presentation.

Editor's note: This transcript has been edited for clarity.

Hi, I'm Jessica Steen, an assistant professor at Nova Southeastern University College of Optometry in Fort Lauderdale, Florida. We're in San Diego at the American Academy of Optometry meeting, and I've had the opportunity to discuss an ophthalmic therapeutic update with our colleagues.

Now the key takeaway here is to think beyond that top line, exciting, headline-making results of clinical trial data. When you think a little bit deeper and really dig into the secondary endpoints—and to think about some of the potential safety signals, this is where we really start to determine maybe indications or patient selection for a particular product. And then we can also start to think about—as we're seeing patients in clinic—maybe some of the clinical signs that could be associated with that particular medication.

We absolutely have the unmet need of sustained release and sustained delivery products and there is continued investigation despite a very recent setback. We have had a new regulatory approval of a true first in class intraocular pressure lowering medication, and we are on the verge of a regulatory decision about a potential treatment option for a as a first in disease state option for the treatment of dry macular degeneration and specifically geographic atrophy.

You know, it's such an exciting time to be in the eye healthcare space and optimizing clinical outcomes really starts with understanding the options that are available.

Related Videos
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
Jessica Steen, OD, FAAO, discusses systemic medication and ocular adverse effects at Vision Expo East 2024
Filomena Ribeiro, MD, PhD, FEBO sits down with Ophthalmology Times Europe to discuss the realities of being a woman in ophthalmology
The Vision Council CEO Ashley Mills gives a preview of the 2024 Vision Expo East event
© 2024 MJH Life Sciences

All rights reserved.